BioXcel Therapeutics Reports $14.7 Million Net Loss and Advances Neuroscience Pipeline

BioXcel Therapeutics, Inc. reported a net loss of $14.7 million for the three months ended June 30, 2026, compared to a net loss of $19.2 million for the same period in 2025. For the six-month period ended June 30, 2026, the company incurred a net loss of $27.4 million, an increase from $26.4 million in the first six months of 2025. Product revenue, net, saw an increase to $182,000 for the three months ended June 30, 2026, from $120,000 in the prior year's comparable quarter, and rose to $388,000 for the six-month period, up from $288,000 in the same period of 2025.

The company's financial statements indicate a significant decrease in operating expenses, with total operating expenses for the three months ended June 30, 2026, at $10.4 million, down from $16.0 million in the same period of 2025. This reduction was primarily driven by lower research and development expenses, which decreased by 69% to $3.2 million for the three-month period, largely due to the completion of key clinical trials. Selling, general, and administrative expenses, however, increased by 28% to $7.2 million for the three months ended June 30, 2026, primarily due to higher professional fees, including legal costs.

In terms of strategic and operational developments, BioXcel Therapeutics continues to advance its neuroscience pipeline, with a focus on BXCL501. The company submitted a supplemental New Drug Application (sNDA) to the FDA for IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia, with a target action date of November 14, 2026. The company also reported progress on its TRANQUILITY program for agitation associated with Alzheimer's dementia, planning for an In-Care Phase 3 trial pending funding.

The company's liquidity remains a significant concern, with cash, cash equivalents, and restricted cash totaling $13.8 million as of June 30, 2026. Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern for at least 12 months from the issuance date of the financial statements. BioXcel Therapeutics is actively pursuing strategic alternatives, including a sale, merger, or additional financing, but no definitive agreements have been reached. The company has also entered into multiple amendments to its Credit Agreement with Oaktree, which include reduced liquidity covenants and requirements to enter into definitive agreements for repayment or alternative capital solutions by specific dates in August 2026.